Literature DB >> 9529469

Hyponatremic seizure in a child using desmopressin for nocturnal enuresis.

M B Donoghue1, M E Latimer, H L Pillsbury, J H Hertzog.   

Abstract

BACKGROUND: Intranasal desmopressin has been used extensively to treat primary nocturnal enuresis. While it has proven to be a safe, effective agent for many who are affected by this condition, the potential for complications exists.
OBJECTIVES: To report a case of severe hyponatremia associated with a generalized tonic-clonic seizure in a 10-year-old boy who had been receiving intranasal desmopressin nightly for nocturnal enuresis and to briefly review therapeutic options for nocturnal enuresis; and to present the role of desmopressin.
SETTING: Georgetown University Medical Center, Washington, DC. INTERVENTION: Fluid restriction and intravenous isotonic saline solution with 5% dextrose was administered to raise the serum sodium level. OUTCOME: Prevention of further seizures with normalization of serum sodium levels without any obvious neurological sequelae.
CONCLUSIONS: This case illustrates the importance of weighing the benefits and risks of intranasal desmopressin therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9529469     DOI: 10.1001/archpedi.152.3.290

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  4 in total

1.  Hyponatraemic convulsion secondary to desmopressin treatment for primary enuresis.

Authors:  D C Apakama; A Bleetman
Journal:  J Accid Emerg Med       Date:  1999-05

Review 2.  Enuresis: current concepts.

Authors:  D E Greydanus; A D Torres; D M O'Donnell; A N Feinberg
Journal:  Indian J Pediatr       Date:  1999 May-Jun       Impact factor: 1.967

Review 3.  Management of nocturnal enuresis - myths and facts.

Authors:  Rajiv Sinha; Sumantra Raut
Journal:  World J Nephrol       Date:  2016-07-06

Review 4.  Comparative tolerability of drug treatment for nocturnal enuresis in children.

Authors:  Dominik Müller; Charles C Roehr; Paul Eggert
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.